Eli Lilly shares jump on two big updates and Jim Cramer is so here for it

The Biden administration proposed a rule change that would expand access to Eli Lilly's Zepbound. And an obesity drug competitor released disappointing results.

from US Top News and Analysis https://ift.tt/BKNVbEz